Transarterial Injection of <sup>131</sup>I-Lipiodol, Compared with Chemoembolization, in the Treatment of Unresectable Hepatocellular Cancer

Marelli, Laura; Shusang, Vibhakorn; Buscombe, J. R.; Stigliano, Rosa; Davies, Neil; Tibballs, Jonathan; Patch, David; Meyer, Tim; Burroughs, Andrew K.

doi:10.2967/jnumed.108.060558

Cited by 34 publications

(25 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 Marelli et al, in a retrospective comparative trial, also demonstrated similar survival outcomes, but again showed that iodine-131-Lipiodol was superior to TACE in patients with advanced clinical staging or portal vein thrombosis. 16 However, the constraints surrounding the need for a period of hospital admission after the procedure in a radioisolation facility has made TACE a more attractive and evidence-based therapeutic option, for which it has been further evaluated in 3 randomized trials comparing against best supportive/ medical care. [19][20][21] It is unlikely that a comparative trial between iodine-131-Lipiodol and TACE is feasible in this present day.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intra‐arterial iodine‐131‐lipiodol for unresectable hepatocellular carcinoma

Chua

Chu

Butler

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND: Hepatic artery administration of iodine-131-Lipiodol serves as a modality that delivers targeted radiation therapy to hepatocellular carcinoma. Its efficacy has been promising according to trials conducted in the adjuvant setting after hepatic resection. Further investigation of its role in the palliative setting is warranted. METHODS: A retrospective review of 72 patients with unresectable hepatocellular carcinoma treated with iodine-131-Lipiodol and followed up by the St. George Hospital Sydney's hepatobiliary service was conducted. Efficacy of treatment was determined based on progression-free and overall survival as the endpoints using the Kaplan-Meier method. RESULTS: Sixty men and 12 women with a mean age of 65 years (standard deviation ¼ 11) underwent iodine-131-Lipiodol treatment. Chronic viral hepatitis was present in 29 (41%) patients. Fifty (69%) patients were Child-Pugh class A. Median progression-free survival was 6 months, and overall survival was 14 months; the 1-, 2-, and 3-year survival rates were 52%, 33% and 20%, respectively. Factors associated with survival include the American Joint Committee on Cancer stage (P ¼.03), Barcelona Clinic Liver Cancer stage (P ¼.05), Cancer of the Liver Italian Program score (P ¼.008), tumor size (P ¼.01), extrahepatic disease (P < .001), previous surgery (P ¼.02), and response to treatment (P < .001). The response to treatment was identified through a multivariate analysis as the single independent predictor for survival (hazard ratio, 3.5; 95% confidence interval, 2.2-5.4; P < .001). CONCLUSIONS: Encouraging survival outcomes may be derived through administration of iodine-131-Lipiodol in patients with unresectable hepatocellular carcinoma. The overall success of treatment may be determined by the response to treatment. Cancer 2010;116:4069-77.

show abstract

Section: Discussionmentioning

confidence: 99%

“…[13][14][15][16] The heterogenous survival results reflect the selection of patients for treatment. In the study by Boucher et al, 14 a significant Figure 3.…”

Section: Discussionmentioning

confidence: 99%

Intra‐arterial iodine‐131‐lipiodol for unresectable hepatocellular carcinoma

Chua

Chu

Butler

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

“…131I-Lipiodol therapy in patients with cirrhosis and HCC has an efficacy similar to that of TACE/TAE therapy 28,32,42 . However 131I-Lipiodol appears to be of more benefit in patients with advanced disease, for example, in those with Okuda stage III disease or BCLC stage D as well as in patients with PVT 42 .…”

Section: I-lipiodol-therapy Versus Tae and Tacementioning

confidence: 98%

“…However 131I-Lipiodol appears to be of more benefit in patients with advanced disease, for example, in those with Okuda stage III disease or BCLC stage D as well as in patients with PVT 42 . PVT patients receiving 131I-Lipiodol lived on average almost a year longer than those treated with TACE or TAE.…”

Section: I-lipiodol-therapy Versus Tae and Tacementioning

confidence: 99%

Therapy of Hepatocellular Carcinoma with Iodine-131-Lipidiol

Ahmadzadehfar¹,

Sabet²,

Biersack³

et al. 2012

Hepatocellular Carcinoma - Clinical Research

View full text Add to dashboard Cite

“…A recent retrospective trial showed similar survival rates for 124 patients with unresectable HCC treated with either 131 I-lipiodol or chemoembolization (69 vs 62% at 1 year, respectively). However, patients with portal vein thrombosis had better survival if treated with 131 I-lipiodol than chemoembolization [63]. Transarterial 166 Ho, a neutronactivated radioactive isotope, has been newly introduced and resulted in a 78% response rate in a recent Phase II study for Quick, Lo, Mayr & Kim patients with a single HCC at least 3 cm in size [64].…”

Section: Additional Radioactive Isoptopesmentioning

confidence: 98%

Radiation therapy for intrahepatic malignancies

Quick

Mayr

et al. 2009

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Historically, radiation was not used in the management of hepatocellular carcinoma and liver metastasis because of the low tolerance of the liver to radiation. More recently, improvements in radiation delivery using advanced techniques, such as 3D conformal radiation therapy, intensity-modulated radiation therapy, image-guided radiation therapy, stereotactic body radiation therapy, proton-beam therapy and internal radiation therapy, have enabled partial and selective irradiation of the liver with promising response rates and toxicity profiles. This review will discuss the different techniques of radiation that can now be used to treat intrahepatic malignancies and the important clinical studies in the medical literature.

show abstract

Transarterial Injection of ¹³¹I-Lipiodol, Compared with Chemoembolization, in the Treatment of Unresectable Hepatocellular Cancer

Cited by 34 publications

References 27 publications

Intra‐arterial iodine‐131‐lipiodol for unresectable hepatocellular carcinoma

Intra‐arterial iodine‐131‐lipiodol for unresectable hepatocellular carcinoma

Therapy of Hepatocellular Carcinoma with Iodine-131-Lipidiol

Radiation therapy for intrahepatic malignancies

Contact Info

Product

Resources

About

Transarterial Injection of 131I-Lipiodol, Compared with Chemoembolization, in the Treatment of Unresectable Hepatocellular Cancer

Cited by 34 publications

References 27 publications

Intra‐arterial iodine‐131‐lipiodol for unresectable hepatocellular carcinoma

Intra‐arterial iodine‐131‐lipiodol for unresectable hepatocellular carcinoma

Therapy of Hepatocellular Carcinoma with Iodine-131-Lipidiol

Radiation therapy for intrahepatic malignancies

Contact Info

Product

Resources

About

Transarterial Injection of ¹³¹I-Lipiodol, Compared with Chemoembolization, in the Treatment of Unresectable Hepatocellular Cancer